People living with diabetes in the UK who use Abbott's FreeStyle LibreLink app with FreeStyle Libre glucose sensing technology, can now connect it to Novo Nordisk's smart connected pens. This allows people living with diabetes to see how different factors like dose timing and the amount of insulin taken impact their individual glucose patterns. Healthcare professionals often ask people living with diabetes to keep a record of their insulin dose data, to add context to their glucose readings.

Completing this process manually can be time-consuming and result in missing, incomplete, or inaccurate data. When people tap Novo Nordisk's smart connected pens, NovoPen® 6 or NovoPen Echo® Plus, against their smartphone their insulin dose data is automatically uploaded to the FreeStyle LibreLink app. It can then be viewed alongside their glucose data in one place.

After the COVID-19 pandemic, the Primary Care Diabetes Society (PCDS) forecasted diabetes review backlogs of up to a year. Smart connected pens and glucose sensing technology could play a role to support the NHS in clearing this backlog, as data show they may help people with diabetes reduce their risk of hyper or hypo-glycaemic events. Novo Nordisk believes that digital health solutions can support people with diabetes and their healthcare professionals with reliable information.